| Patient | Arthur Ashe |
|---|---|
| Date of birth | 1980-07-10 |
| Identifiers | MRN HR-ML013-SYN; SSN (made up) 000-13-6620 |
| Document date | 2026-02-09 |
| Author | Vivian Tolliver, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week potassium and creatinine check, second hepatitis B vaccine, and same-day infectious diseases consultation. [S]
Mr. Ashe returns four weeks after his first visit and is seen by Dr. Rao of infectious diseases on the same day. He takes bictegravir, emtricitabine, and tenofovir alafenamide each morning and trimethoprim-sulfamethoxazole twice a day, and has missed no doses. He started ezetimibe four weeks ago without muscle aches. He has had no headache, seizure, or weakness, and his right hand feels normal. He has had no rash, fever, cough, or breathlessness, and no chest pain. He is sleeping better than at the first visit and has started to coach again two afternoons a week. He has told no one new about his diagnosis and asked again that his results go only to him. [S]
| Element | Detail |
|---|---|
| Adherence | No missed doses of any medicine |
| New medicine | Ezetimibe for four weeks; no side effects |
| Neurological | No headache, seizure, or weakness |
| Heart | No chest pain; no nitroglycerin use |
| Privacy | Results to him only, by secure message |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight up 0.6 kg |
| Integumentary | Negative | No rash on trimethoprim-sulfamethoxazole |
| Cardiovascular | Negative | No chest pain or palpitations |
| Neurological | Negative | No headache, seizure, numbness, or weakness |
| Psychiatric | Negative | Mood improving; sleeping better; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium | One tablet by mouth once daily | Oral route | 2025-09-25 | active | S |
| Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intake | Three tablets by mouth daily after a 200 mg loading dose | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intake | Three tablets by mouth every 6 hours | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intake | Two tablets by mouth daily | Oral route | 2025-09-11 to 2025-10-23 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2025-10-23 to 2026-10-19 | completed | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2016-07-31 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2016-08-01 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2016-08-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-09 | Body height | 185 | cm | S |
| 2026-02-09 | Body weight | 72.6 | kg | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-02-09 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-02-09 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-02-09 | Heart rate | 70 | /min | S |
| 2026-02-09 | Respiratory rate | 14 | /min | S |
| 2026-02-09 | Body temperature | 36.6 | Cel | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 79 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
Vital signs recorded on 2026-02-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and composed; weight 72.6 kg, blood pressure 116/72 |
| Skin and mouth | No rash; no thrush |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | Grip strength and fine finger movements equal on both sides; no focal deficit |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection | active | confirmed | B20 | S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled. |
| Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy | active | confirmed | B58.2 | S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass. |
| Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operations | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the history remains D. |
| Old myocardial infarction at age 36 | active | confirmed | I25.2 | S — Synthetic coded history of the documented 1979 heart attack. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Up to date | 42 copies/mL four weeks ago, falling from 186,000 at diagnosis; next at three months |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Up to date | 156 cells/uL four weeks ago; next at three months |
| Laboratory | HIV genotype resistance test | At diagnosis, before ART; again if the viral load rebounds | Up to date | No resistance mutations on the genotype sent before ART in the hospital |
| Laboratory | HLA-B*5701 test | Only before abacavir is considered | Not indicated | Abacavir is avoided because of its association with myocardial infarction in people with coronary disease |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no antacid, calcium, iron, or new medicine |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Up to date | Hemoglobin 13.0 g/dL, white cells 4.2, platelets 198 four weeks ago; next at three months |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.8 mmol/L, creatinine 1.16 mg/dL, eGFR 79; stable |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Deferred | Not done when tenofovir alafenamide was started in the hospital or at intake, a deviation from the DHHS and HIVMA guidance. Creatinine is stable, so no harm is evident. Corrective action: urine albumin-to-creatinine ratio ordered with the three-month blood tests |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Up to date | ALT 30 U/L four weeks ago |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | Trimethoprim-sulfamethoxazole double strength twice daily, the alternative maintenance regimen; CD4 156, so it continues |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | Covered by the trimethoprim-sulfamethoxazole maintenance dose |
| Medication safety | Mycobacterium avium complex prophylaxis | Not recommended for people who start ART promptly | Not indicated | On fully active ART since the hospital |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms; grip and fine finger movements equal |
| Self-management | Hepatitis B vaccine series and antibody check | Two doses four weeks apart; surface antibody 1 to 2 months after the last dose | Completed today | Dose 2 given today; antibody check at three months |
| Self-management | Meningococcal ACWY vaccine | Two doses at least 8 weeks apart, then every 5 years | Up to date | Dose 1 four weeks ago; dose 2 at three months |
| Self-management | Live vaccines (MMR, varicella) | Contraindicated while CD4 below 200 | Not indicated | CD4 156; immune to measles, mumps, rubella, and varicella by serology in the hospital |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Results go to him alone by secure message; he has not chosen to tell anyone new; peer support group details given again |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Up to date | PHQ-9 5 four weeks ago; mood improving |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 116/72 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 72.6 kg, BMI 21.2; coaching two afternoons a week |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three; atorvastatin 80 mg has no interaction with bictegravir |
| Medication safety | Beta-blocker | First year after myocardial infarction, or with LVEF 50 percent or less, angina, or another indication | Not indicated | Myocardial infarction ten years ago; no angina, heart failure, or arrhythmia; blood pressure normal |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina; nitroglycerin not used; chest-pain plan reviewed |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Due | LDL 88 mg/dL at intake; ezetimibe added; recheck with the three-month blood tests |
| Laboratory | Lipoprotein(a), once in adulthood | Once in adulthood | Due | Not on record; with the three-month blood tests |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |
| Referral | Infectious diseases consultation | At diagnosis, then as advised | Completed today | Seen by Dr. Rao today |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026)
Follow-up: Three-month visit with blood and urine tests, the second meningococcal dose, and the first zoster dose. Results by secure message. Next scheduled visit 2026-04-13: three-month HIV and lipid review. [S]